Optimal Testing Choice and Diagnostic Strategies for Latent Tuberculosis Infection Among US-Born People Living with Human Immunodeficiency Virus (HIV). (6th August 2020)
- Record Type:
- Journal Article
- Title:
- Optimal Testing Choice and Diagnostic Strategies for Latent Tuberculosis Infection Among US-Born People Living with Human Immunodeficiency Virus (HIV). (6th August 2020)
- Main Title:
- Optimal Testing Choice and Diagnostic Strategies for Latent Tuberculosis Infection Among US-Born People Living with Human Immunodeficiency Virus (HIV)
- Authors:
- Pettit, April C
Stout, Jason E
Belknap, Robert
Benson, Constance A
Séraphin, Marie Nancy
Lauzardo, Michael
Horne, David J
Garfein, Richard S
Maruri, Fernanda
Ho, Christine S - Abstract:
- Abstract: Background: Increased risk of progression from latent tuberculosis infection (LTBI) to tuberculosis (TB) disease among people living with human immunodeficiency virus (HIV; PLWH) prioritizes them for LTBI testing and treatment. Studies comparing the performance of interferon gamma release assays (IGRAs) and the tuberculin skin test (TST) among PLWH are lacking. Methods: We used Bayesian latent class analysis to estimate the prevalence of LTBI and diagnostic characteristics of the TST, QuantiFERON Gold In-Tube (QFT), and T.SPOT-TB (TSPOT) among a prospective, multicenter cohort of US-born PLWH ≥5 years old with valid results for all 3 LTBI tests using standard US cutoffs (≥5 mm TST, ≥0.35 IU/mL QFT, ≥8 spots TSPOT). We also explored the performance of varying LTBI test cutoffs. Results: Among 1510 PLWH (median CD4+ count 532 cells/mm 3 ), estimated LTBI prevalence was 4.7%. TSPOT was significantly more specific (99.7%) and had a significantly higher positive predictive value (90.0%, PPV) than QFT (96.5% specificity, 50.7% PPV) and TST (96.8% specificity, 45.4% PPV). QFT was significantly more sensitive (72.2%) than TST (54.2%) and TSPOT (51.9%); negative predictive value of all tests was high (TST 97.7%, QFT 98.6%, TSPOT 97.6%). Even at the highest cutoffs evaluated (15 mm TST, ≥1.00 IU/mL QFT, ≥8 spots TSPOT), TST and QFT specificity was significantly lower than TSPOT. Conclusions: LTBI prevalence among this cohort of US-born PLWH was low compared to non-US bornAbstract: Background: Increased risk of progression from latent tuberculosis infection (LTBI) to tuberculosis (TB) disease among people living with human immunodeficiency virus (HIV; PLWH) prioritizes them for LTBI testing and treatment. Studies comparing the performance of interferon gamma release assays (IGRAs) and the tuberculin skin test (TST) among PLWH are lacking. Methods: We used Bayesian latent class analysis to estimate the prevalence of LTBI and diagnostic characteristics of the TST, QuantiFERON Gold In-Tube (QFT), and T.SPOT-TB (TSPOT) among a prospective, multicenter cohort of US-born PLWH ≥5 years old with valid results for all 3 LTBI tests using standard US cutoffs (≥5 mm TST, ≥0.35 IU/mL QFT, ≥8 spots TSPOT). We also explored the performance of varying LTBI test cutoffs. Results: Among 1510 PLWH (median CD4+ count 532 cells/mm 3 ), estimated LTBI prevalence was 4.7%. TSPOT was significantly more specific (99.7%) and had a significantly higher positive predictive value (90.0%, PPV) than QFT (96.5% specificity, 50.7% PPV) and TST (96.8% specificity, 45.4% PPV). QFT was significantly more sensitive (72.2%) than TST (54.2%) and TSPOT (51.9%); negative predictive value of all tests was high (TST 97.7%, QFT 98.6%, TSPOT 97.6%). Even at the highest cutoffs evaluated (15 mm TST, ≥1.00 IU/mL QFT, ≥8 spots TSPOT), TST and QFT specificity was significantly lower than TSPOT. Conclusions: LTBI prevalence among this cohort of US-born PLWH was low compared to non-US born persons. TSPOT's higher PPV may make it preferable for testing US-born PLWH at low risk for TB exposure and with high CD4+ counts. Abstract : Latent tuberculosis infection prevalence was low among this cohort of US-born persons .5 years old living with human immunodeficiency virus (HIV). T-SPOT.TB was more specific than the tuberculosis skin test or QuantiFERON Gold in-tube, resulting in fewer false positives. … (more)
- Is Part Of:
- Clinical infectious diseases. Volume 73:Number 7(2021)
- Journal:
- Clinical infectious diseases
- Issue:
- Volume 73:Number 7(2021)
- Issue Display:
- Volume 73, Issue 7 (2021)
- Year:
- 2021
- Volume:
- 73
- Issue:
- 7
- Issue Sort Value:
- 2021-0073-0007-0000
- Page Start:
- e2278
- Page End:
- e2284
- Publication Date:
- 2020-08-06
- Subjects:
- human immunodeficiency virus (HIV) -- latent tuberculosis infection (LTBI) -- latent class analysis (LCA) -- tuberculin skin test (TST) -- interferon gamma release assay (IGRA)
Communicable diseases -- Periodicals
616.905 - Journal URLs:
- http://cid.oxfordjournals.org ↗
http://ukcatalogue.oup.com/ ↗
http://www.journals.uchicago.edu/CID/journal ↗
http://www.jstor.org/journals/10584838.html ↗ - DOI:
- 10.1093/cid/ciaa1135 ↗
- Languages:
- English
- ISSNs:
- 1058-4838
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.293860
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25053.xml